Daniel Peeper - Selected Publications#

1. Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden D, Bleijerveld O, Kuilman T, Kluin R, Sun C, Voest E, Ju Y, Schumacher T, Altelaar M, McDermott U, Adams D, Blank C, Haanen J and Peeper DS. BRAFV600E kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Reports, in press.

2. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, Voest EE, Schumacher TN, Blank CU, Adams DJ, Haanen JB, Peeper DS. Intra- and inter-tumor heterogeneity in a vemurafenib- resistant melanoma patient and derived xenografts. EMBO Mol Med. 2015 Jun 23. pii: e201404914. doi: 10.15252/emmm.201404914.

3. Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O. CopywriteR: DNA copy number detection from off-target sequence data. Genome Biology 2015, 16(1), 49. doi:10.1186/s13059-015-0617-1

4. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712. PMID: 25502142

5. Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS. Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Rep. 2014 Nov 20;9(4):1375-86. doi: 10.1016/j.celrep.2014.10.024. Epub 2014 Nov 6. PMID: 25456132

6. Smit MA, Maddalo G, Greig K, Raaijmakers LM, Possik PA, van Breukelen B, Cappadona S, Heck AJ, Altelaar AM, Peeper DS. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol Syst Biol. 2014 Dec 23;10(12):772. doi: 10.15252/msb.20145450.

7. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov V, MacKay G, van der Burg S, Verdegaal E, Cascante M, Shlomi T, Gottlieb E, Peeper DS. (2013) A critical role for the mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498(7452):109-12. doi: 10.1038/nature12154. Epub 2013 May 19.

8. Vredeveld LCW, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS. (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev doi:10.1101/ gad.187252.112.

9. Kuilman T., Michaloglou C., Vredeveld L.C.W., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., and Peeper D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-31.

10. Michaloglou C, Vredeveld L.C.W., Soengas M.S., Denoyelle C., Kuilman T., Van der Horst C.M.A.M., Majoor D.M., Shay J.W., Mooi W.J. and Peeper D.S. (2005). BRAFE600- associated senescence-like cell cycle arrest of human nevi. Nature 436, 720-724.

11. Douma, S., T van Laar, J Zevenhoven, R Meuwissen, E van Garderen & DS Peeper. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034–1039 (2004).